ClinicalTrials.gg
Status unknownNCT05622656Updated Nov 18, 2022

Dexmedetomidine Reduce Postoperative Pain of C-section

A Phase 4 interventional study of Dexmedetomidine and Placebo in Pain, Postoperative, sponsored by First People's Hospital of Chenzhou. Status unknown at 1 site in China. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by First People's Hospital of Chenzhou · Phase 4, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.

Planned enrollment
69th of 136
80 · median 85
Started
2022
with 12 others
Phase 4
49 of 136
14 open now
Registered
73rd of 136
by date

Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 69th largest by planned enrollment, is one of 13 that started in 2022, is one of 49 in phase 4, and was the 73rd registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing dexmedetomidine in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of this study was to make sure whether the infiltration of dexmedetomidine around the uterus can reduce the pain of cesarean section surgery.Studies have shown that the use of local anesthetic infiltration around the uterus can reduce pain after cesarean section surgery.In observed group, 50ug of dexmedetomidine (volume 10ml) was infiltrated around the uterus at the end of the caesarean section, while in controled group, 10ml normal saline as placebo was infiltrated around the uterus. VASs was accessed in 2h 12h,24h,48h after surgery.

Read the detailed description

Cesarean section is one of the most common inpatient surgical procedures in the world, and in China, with the implementation of the comprehensive two-child policy, the number of elderly mothers and patients undergoing another cesarean section has gradually increased, and the cesarean section rate has also gradually increased; however, despite the many measures taken to control post-cesarean pain, there are still many people with inadequate pain control. Pain after cesarean delivery can have a significant negative impact on both the physical and psychological aspects of the mother and lead to complications such as thromboembolism, chronic pain and depression. Currently, a variety of methods are available to relieve post-cesarean pain, such as patient controlled intravenous analgesia (PCIA), patient controlled epidural analgesia (PCEA), transversus abdominis plane block (TAPB), etc. However, these analgesic methods are not perfect, and each has its own shortcomings. The currently prevalent ERAS concept focuses on multimodal analgesia and minimizing the use of opioids to reduce perioperative stress and reduce opioid nociceptive allergy. Compared to the technical difficulties, risks and other potential complications, abdominal medication has some advantages.

Intraperitoneal spray of local anesthetic (IPLA) has become a commonly used method of analgesia after laparotomy. Intraperitoneal administration is simple, safe, and can relieve postoperative pain, shorten the length of hospital stay, and improve comfort.

One study showed that the use of intraperitoneal infusion of lidocaine (400 mg) improved pain management in the early postoperative period after cesarean section and reduced the number of patients requiring systemic opioids in the immediate postpartum period. It has also been demonstrated that in patients undergoing bariatric surgery, intraoperative intraperitoneal spraying of ropivacaine resulted in effective postoperative pain relief, less need for morphine postoperatively, earlier activity and feeding, and shorter hospital stays, that effective pain control encouraged early bedtime, reduced the risk of thrombosis, and reduced pulmonary complications such as atelectasis or pneumonia, and that 24-hour postoperative blood counts showed significantly lower leukocyte counts were significantly lower.

Dexmedetomidine is a potent, multifunctional, highly selective α2-adrenergic agonist. It has been shown in the literature that the application of dexmedetomidine can effectively reduce the perioperative stress response, significantly reduce the dosage of opioids in the perioperative period and prevent the transformation of acute postoperative pain into chronic pain. Some animal experiments have shown that dexmedetomidine alone has obvious analgesic effect when sprayed intraperitoneally with 12.5μg/kg of dexmedetomidine, the peak time is 20-30 minutes after administration, and the duration of action is 90 minutes. There are few studies on the use of dexmedetomidine alone intraperitoneally to reduce postoperative pain in the clinical setting and there is a lack of data to support its use in post-caesarean pain.

The purpose of this study was to assess the effect of intraperitoneal dexmedetomidine 50μg at the end of cesarean delivery on maternal pain scores and satisfaction in the context of a multimodal analgesic protocol.

The investigators hypothesized that intraperitoneal dexmedetomidine would reduce VAS pain scores, reduce the number of patient-administered intravenous analgesic pump uses and opioid-related side effects, and increase maternal satisfaction after cesarean delivery.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Intraperitoneal spraying
  • Dexmedetomidine
  • Cesarean section
  • Postoperative analgesia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA Ⅰ or Ⅱ patients
  • 18-50 years of age
  • \<40
  • Term pregnancy
  • Singleton pregnancy
  • Spinal anesthetic
  • Patients who have given pre-operative informed written consent

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse or are unable to give consent
  • ASA>Ⅱ
  • Multiple gestation
  • Chronic pain
  • allergic to any medication in the study protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Intraperitoneal instillation of normal saline

    Drug: Placebo

  • Active comparator
    Dexmedetomidines

    Intraperitoneal instillation Dexmedetomidine 5ug/ml (10ml,50ug)

    Drug: Dexmedetomidine

Interventions

  • Dexmedetomidine 0.0005%

    Also known as: Dexmedetomidine Hydrochloride

  • DrugPlacebo

    0.9% Sodium Chloride Solution

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. Pain Score (VAS) 48hr rest

    VAS score (VAS 0-10 cm) for maternal pain on rest at 48 hours postcesarean delivery

    Time frame: 48 hours

  2. Pain Score (VAS) 48hr movement

    VAS score (VAS 0-10 cm) for maternal pain on movement at 48 hours postcesarean delivery

    Time frame: 48 hours

Secondary outcomes

  1. Pain Score (VAS) 2hr rest

    VAS score (VAS 0-10 cm) for maternal pain on rest at 2 hours postcesarean delivery

    Time frame: 2 hours

  2. Pain Score (VAS) 2hr movement

    VAS score (VAS 0-10 cm) for maternal pain on movement at 2 hours postcesarean delivery

    Time frame: 2 hours

  3. Pain Score (VAS) 24hr rest

    VAS score (VAS 0-10 cm) for maternal pain on rest at 24 hours postcesarean delivery

    Time frame: 24 hours

  4. Pain Score (VAS) 24hr movement

    VAS score (VAS 0-10 cm) for maternal pain on movement at 24 hours postcesarean delivery

    Time frame: 24 hours

  5. Effective presses of PCIA pump 48hrs

    Number of effective presses of PCIA pump at 48 hours postcesarean delivery

    Time frame: 48 hours

  6. Patient satisfaction 48hrs

    Patient satisfaction at 48 hours postcesarean

    Time frame: 48 hours

  7. Bowel function

    Return of bowel function as assessed by passing flatus

    Time frame: 48 hours

  8. Side Effect scores

    Nausea, vomiting and pruritis score at 24 hours and 48 hours postcesarean delivery

    Time frame: 48 hours

  9. Flurbiprofen Axetil consumption 48hrs

    Flurbiprofen Axetil consumption within 48 hours postcesarean delivery

    Time frame: 48 hours

07

Study locations

1 of 1 sites recruiting
  • Zhiming Zhang
    Chenzhou, Hunan 423000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2022; primary completion for Mar 2023, 3 months later.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 3 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2022
First posted
Nov 18, 2022
StartEst.
Dec 1, 2022
Primary completionEst.
Mar 31, 2023
CompletionEst.
Mar 31, 2023
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05622656
Lead sponsor
First People's Hospital of Chenzhou
Responsible party
zhiming zhang (MD, Ph.D, First People's Hospital of Chenzhou) — Principal investigator
First posted
Nov 18, 2022
Start date
Dec 1, 2022 (estimated)
Primary completion
Mar 31, 2023 (estimated)
Completion
Mar 31, 2023 (estimated)
Last update
Nov 18, 2022

Study contacts

Zhiming Zhang, Ph.D
Contact
otc0735@163.com
13875555649
Yuan Qin, MD
Contact
uscqinyuan@163.com
13657381087

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion